Every S-3 that iSpecimen Inc. (ISPC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow ISPC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ISPC filings page.
iSpecimen Inc. registers 488,290 shares of Common Stock for resale by selling stockholders. This prospectus covers up to 488,290 shares of common stock consisting of 85,202 Shares issued in the May 2026 Private Placement and 403,088 Warrant Shares issuable upon exercise of Pre-Funded Warrants, to be offered and resold from time to time by the selling stockholders. The Company will not receive proceeds from these resales; it may receive nominal proceeds (approximately $40.00) only if the Pre-Funded Warrants are exercised for cash at $0.0001 per share. The shares registered may be sold in public or private transactions at prevailing or negotiated prices; timing and amounts of any sales are determined by the selling stockholders.
iSpecimen Inc. is registering 101,000,000 shares of common stock for resale by investors who hold Series C Convertible Non-Voting Preferred Stock issued in a December 2025 private placement. These “Conversion Shares” will become issuable upon conversion of 6,875 Series C preferred shares and any related anti-dilution adjustments under the Certificate of Designation. After the offering, iSpecimen would have 110,771,046 common shares outstanding if all Conversion Shares are issued.
The company will not receive proceeds from sales by the selling stockholders. It already raised approximately $5.5 million in gross proceeds in the December 2025 private placement, paying a 4% cash commission to E.F. Hutton & Co. and using $2,000,000 for marketing and investor relations services from IR Agency LLC, with the remainder for working capital and general corporate purposes. iSpecimen notes that large resales under this registration could put downward pressure on its share price.
iSpecimen operates an online biospecimen marketplace connecting healthcare providers with life science researchers. The company recently regained compliance with Nasdaq’s stockholders’ equity rules but remains out of compliance with the $1.00 minimum bid price requirement and has until May 18, 2026 to cure this deficiency. Its common stock trades on the Nasdaq Capital Market under the symbol “ISPC”.